Topics

Companies Related to "Regenxbio Inks Viral Vector Rights Deal With Pfizer" [Most Relevant Company Matches] [Advanced Search Results] RSS

02:09 EST 15th November 2019 | BioPortfolio

Here are the most relevant search results for "Regenxbio Inks Viral Vector Rights Deal With Pfizer" found in our extensive corporate database of over 50,000 company records.

Showing "Regenxbio Inks Viral Vector Rights Deal With Pfizer" Companies 1–25 of 892

Relevant

SIRION Biotech GmbH

Founded in 2005, SIRION Biotech is a global leader in developing research and commercial grade viral vector solutions for industry and academic partners who are developing gene therapies and vaccines. With the broadest vector portfolio that produces products with the highest yield, purity and quality, SIRION provides reliable, custom-engineered viral vecto...


Genethon

Genethon produces recombinant viral vectors for gene transfer. The vectors can be used for research or preclinical studies. GMP grade vector preparations will be available in the near future.We can either amplify a vector that you are currently using, or design and produce one with the features you need. Initial DNA constructs are assembled, starting from elements you provide to Genethon.You proje...

Cavit Sciences

Cavit Sciences, Inc. (“Cavit”) is a biotechnology company engaged in developing treatments of cancer and viral infections. Our strategy is to develop and commercialize intellectual property rights to treat, prevent and inhibit several major diseases including cancers, viral infections and diseases associated with cancers and viral infections. We currently own three patent applicati...


Transgene

TRANSGENE is a leading integrated gene therapy company, dedicated to the discovery and development of gene delivery technologies and gene therapy products for the treatment of acquired and inherited diseases. The Company's proprietary technology platform consists of five vector families including three of viral origin - adenovirus, retrovirus, vaccinia virus - and two of non viral origin - cellula...

The Pfizer Foundation

The Pfizer Foundation is a charitable organization established by Pfizer Inc. The Foundation is a separate and independent tax-exempt organization. The Foundation’s mission is to promote access to quality health care, to nurture innovation, and to support the community involvement of Pfizer people.

Cold Genesys, Inc.

Cold Genesys Incorporated is a privately held biopharmaceutical company that is focused on delivering innovative conditionally replicative (Rb pathway defective molecule E2F as the viral E1A gene promoter) competent oncolytic adenovirus vector expressing GM-CSF for the treatment of patients with bladder cancer. CGI acquired the intellectual property ...

Vector Capital

Vector Capital is a leading global private equity firm specializing in transformational investments in established technology businesses. Vector identifies and pursues these complex investments in both the private and public markets. Vector actively partners with management teams to devise and execute new financial and business strategies that materially i...

Renata Limited

Historical High-Lights: Founded in 1972 as a subsidiary of Pfizer Inc. Ownership transferred from Pfizer Inc. to local institutions and the general public in 1993. Company name subsequently changed from Pfizer Laboratories (Bangladesh) Limited to Renata Limited.

Cynvec LLC

Cynvec, a privately held biotechnology company, is developing proprietary cancer therapies based on the apoptotic sindbis oncolytic viral vector, a novel technology that targets the over expressed laminin receptor on the surface of many solid tumors without affecting normal cells. Under an exclusive worldwide license from the NYU School of Medicine, Cynvec is developing its lead product, CYN 101, ...

Pfizer Ophthalmics

Pfizer Ophthalmics, a division of Pfizer Inc, is committed to preserving sight and eliminating preventable blindness. Pfizer Ophthalmics discovers, develops and provides leading treatments in ophthalmology to support patients who are at risk of blindness or suffering from vision impairment, and to serve the health care professionals who treat them. Its current product line includes the most presc...

Bristol-Myers Squibb Company & Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize ELIQUIS, an investigational oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb's long-standing strengths in cardiovascular drug development and commercialization with Pfizer’s global scale ...

Transgene S.A.

Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cell...

Pfizer Consumer Healthcare

Centrum Silver

Deal Labs, Inc.

Deal Labs raises capital for private companies, public companies, and pooled investment funds and partnerships including real estate. Deal Labs selectively targets the type of retail and institutional investors who are believed to be best suited for a particular investment, thereby substantially improving and expediting the capital raising process. Rather ...

PharmaVentures Ltd

PharmaVentures is a premier transaction advisory firm; a world leader in partnering, M&A deals and strategic alliances. Our unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes us uniquely placed to support your business in all aspects of deal making and strategic planning. PharmaVentures ...

Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) (“Rocket”) is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AA...

Pfizer Oncology

Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Our strong pipeline, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers, including...

Bavarian Nordic A/S

In 2004 we marked our 10 year anniversary as a company. Over the past decade we have developed the early MVA vector research into a broad commercial vaccine vector technology.

Virus Detection & Diagnostics Virinova

Our unique and proprietory diagnostic technology enables the detection and quantification of viruses without the use of PCR or antibodies - Direct detection of viruses and viral particles - Fast and simple - Suitable for known and unknown viruses Areas of application:Diagnosis and monitoring of viral infections - Known and unknown virusesProcess control in biotechnology - No...

Rocket Pharmaceuticals, Ltd.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (A...

Pfizer Inc. & Bristol-Myers Squibb

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb's long-standing strengths in cardiovascular drug development and commercialization with Pfizer’s global scale and expertise i...

Bristol-Myers Squibb and Pfizer

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb's long-standing strengths in cardiovascular drug development and commercialization with Pfizer’s global scale and expertise i...

Bristol-Myers Squibb Company and Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize Eliquis, an oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb's long-standing strengths in cardiovascular drug development and commercialization with Pfizer’s global scale and expertise in...

Bristol-Myers Squibb-Pfizer Alliance

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb's long-standing strengths in cardiovascular drug development and commercialization with Pfizer’s global scale and expertise i...

The Deal LLC

The Deal LLC (www.TheDeal.com) is a diversified media and information company. We report, analyze and disseminate business and financial news and data that offer fresh insights on the deal economy, a set of interrelated activities, focused on dealmaking of all kinds, whose purpose is to generate corporate and capital growth in a continually changing global...


More From BioPortfolio on "Regenxbio Inks Viral Vector Rights Deal With Pfizer"

Quick Search

Corporate Database Quicklinks